Ajinomoto To Increase Pharmaceutical Business To ¥100 Billion In 2015
This article was originally published in PharmAsia News
Ajinomoto Jan. 29 announced a business plan to increase its pharmaceutical business from ¥15 billion in 2009 to ¥100 billion in 2015
You may also be interested in...
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.